Innoviva (NASDAQ:INVA – Get Free Report) and Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, institutional ownership and valuation.
Profitability
This table compares Innoviva and Shionogi & Co., Ltd. Unsponsored ADR’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Innoviva | 44.13% | 22.91% | 16.67% |
| Shionogi & Co., Ltd. Unsponsored ADR | 37.95% | 14.32% | 10.24% |
Analyst Ratings
This is a summary of current ratings and price targets for Innoviva and Shionogi & Co., Ltd. Unsponsored ADR, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Innoviva | 0 | 2 | 4 | 0 | 2.67 |
| Shionogi & Co., Ltd. Unsponsored ADR | 0 | 0 | 0 | 3 | 4.00 |
Innoviva presently has a consensus target price of $39.00, suggesting a potential upside of 104.19%. Given Innoviva’s higher possible upside, equities research analysts clearly believe Innoviva is more favorable than Shionogi & Co., Ltd. Unsponsored ADR.
Risk and Volatility
Innoviva has a beta of 0.38, suggesting that its share price is 62% less volatile than the S&P 500. Comparatively, Shionogi & Co., Ltd. Unsponsored ADR has a beta of 0.1, suggesting that its share price is 90% less volatile than the S&P 500.
Earnings and Valuation
This table compares Innoviva and Shionogi & Co., Ltd. Unsponsored ADR”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Innoviva | $438.32 million | 3.15 | $271.17 million | $1.99 | 9.60 |
| Shionogi & Co., Ltd. Unsponsored ADR | $3.32 billion | 4.85 | $1.35 billion | $0.90 | 10.51 |
Shionogi & Co., Ltd. Unsponsored ADR has higher revenue and earnings than Innoviva. Innoviva is trading at a lower price-to-earnings ratio than Shionogi & Co., Ltd. Unsponsored ADR, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
99.1% of Innoviva shares are held by institutional investors. Comparatively, 1.9% of Shionogi & Co., Ltd. Unsponsored ADR shares are held by institutional investors. 2.0% of Innoviva shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Innoviva beats Shionogi & Co., Ltd. Unsponsored ADR on 9 of the 15 factors compared between the two stocks.
About Innoviva
Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
About Shionogi & Co., Ltd. Unsponsored ADR
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer’s disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.
Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.
